BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
BenevolentAI has a proven track-record of scientifically validated discoveries. The Benevolent Platform™ powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI also identified Eli Lilly's baricitinib as a repurposing drug candidate for COVID-19, which has been authorised for emergency use by the FDA.
Join our SVP of Informatics and Data, Mark Davies, at the LSX World Congress for a panel on how AI, machine learning & big data are disrupting the drug discovery & development landscape for faster and more accurate lead identification.
Our CEO Joanna Shields joins the World Economic Forum’s Annual Meeting in Davos for two panels on ‘Unlocking the Power of Digital Health’ and the ‘Use of Responsible AI for Societal Gains’.
